Shilpa Biologicals commissions ADC GMP plant in India, offering end-to-end drug substance manufacturing to meet FDA and EMA ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "ADC Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target ...

Shilpa Biologicals commissions ADC drug substance GMP manufacturing facility: Our Bureau, Mumbai Thursday, June 25, 2026, 17:35 Hrs [IST] Shilpa Biologicals Ltd, a subsidiary of S ...

ADC Therapeutics said that the reduction in workforce is driven by the expected completion of LOTIS-5 and LOTIS-7 trials. ・The company expects to deliver on its key clinical, regulatory, and ...

Research-backed strategy produces highly homogeneous antibody-drug conjugates (gsADCs) with consistent DAR and tumor suppression lasting over 50 days after a single dose A new white paper from ...

Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approximately 70-80% Adrian Gillespie, Chief Executive ...

Basel, Switzerland, 8 January 2013 – Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics ...

Abzena has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (ADC) to clinical ...

Shilpa Biologicals, a material subsidiary of Shilpa Medicare, announced the commissioning of a state-of-the-art AntibodyDrug Conjugate (ADC) GMP manufacturing facility, purpose-built and designed to ...